Piper Jaffray (PJC) Analysts Reiterate a "Overweight" Rating on Regeneron Pharms (REGN)
Monday, June 20, 2021 10:40 AM

Related Stories



Equities research analysts at Piper Jaffray (NYSE: PJC) reiterated an "overweight" rating on shares of Regeneron Pharms (NASDAQ: REGN) in a research note to investors on Monday.

Separately, analysts at Leerink initiated coverage on shares of Regeneron Pharms in a research note to investors on Thursday, June 2nd. They set an "outperform" rating on the stock. Also, analysts at Needham & Company raised their price target on shares of Regeneron Pharms from $49.00 to $60.00 in a research note to investors on Monday, May 9th. They now have a "buy" rating on the stock.

Shares of Regeneron Pharms traded down 1.98% during mid-day trading on Tuesday, hitting $52.95. Regeneron Pharms has a 52 week low of $20.45 and a 52 week high of $71.74. The stock's 50-day moving average is $51.75 and its 200-day moving average is $38.85. The company has a market cap of $4.813 billion.

Regeneron Pharmaceuticals, Inc. (Regeneron) is engaged in the research, development and commercialization of therapeutics to treat human disorders and conditions. The Company’s facilities are primarily located in New York. As of December 31, 2009, the Company had one marketed product: ARCALYST (rilonacept) injection for subcutaneous use, which is available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Its late stage programs are rilonacept, which is being developed for the prevention and treatment of gout-related flares; VEGF Trap-Eye, which is being developed in eye diseases using intraocular delivery in collaboration with Bayer HealthCare LLC, and aflibercept (VEGF Trap), which is being developed in oncology in collaboration with the sanofi-aventis Group.

Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.


 

Sponsors

Advertisement


Advertisement